DBV Technologies reports positive results of Viaskin Peanut study

 


	The biopharmaceutical firm reported positive results from the PEOPLE Phase-3 study of Viaskin Peanut in the children suffering from the peanut allergy. 
	Patients produced long-term and durable clinical benefits with an additional two years of treatment.
	The reported treatment represents the largest long-term peanut allergy immunotherapy trial devised till date. 


France headquartered leading biopharmaceutical firm, DBV Technologies has reportedly announced formulating positive topline results of the long time running PEOPLE Phase-3 study of Viaskin Peanut in the children suffering from the allergies of peanuts. It has been reported that the study has been conducted for the children belonging to the ages 4 to 11 years and those allergic to peanut consumption.

For the uninitiated, PEOPLE study is a continuous study meant for evaluating the long-term safety, efficiency, and the tolerability of the peanut allergy treatment, Viaskin Peanut 250 microgram in the patients who have had completed the Phase-3 PEPITES trial.

As per reliable sources, the results showcase long-term clinical benefits as demonstrated by an increase in the eliciting dose (ED), which reduce the chances of reacting to unintentional peanut exposure. Furthermore, the study revealed that over 75.9 per cent of the patients had improved their ED from the standard point whilst nearly 51.8 per cent had reached an ED of minimum 1000 milligram peanut protein by the end of the study.

Speaking of the accomplishment, the Principal Investigator of PEPITES and PEOPLE, and the Director of Allergy and Immunology Center and Section Head at Children’s Hospital, Colorado, Dr. David Fleischer quoted that the new data has aided the overall clinical benefit of Viaskin Peanut. The firm is extremely pleased to obtain the positive results of the trial carried in the patients.

It was reported that nearly three out of the four patients displayed an increase in the ED. He further added that these data also provide a testament to the fact that the treatment might as well reduce the risk of reaction from the accidental exposure. This could be carried out by increasing the threshold reactivity via an option which is optimally safe and convenient.
 

Source credit: https://www.dbv-technologies.com/wp-content/uploads/2020/01/dbv-technologies-reports-positive-three-year-long-term-data-from-the-people-phase-iii-open-label-extension-study-of-viaskin-peanut-in-children-with-peanut-allergy.pdf